This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perilli, M. Articles by Amicosante, G. Search for Related Content PubMed PubMed Citation Articles by Perilli, M. Articles by Amicosante, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2537-2539, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

TEM-72, a New Extended-Spectrum -Lactamase Detected in Proteus mirabilis and Morganella morganii in Italy

Dipartimento di Scienze e Tecnologie Biomediche, Cattedra di Enzimologia, Università di L'Aquila, L'Aquila,¹ Dipartimento di Biologia Molecolare, Sezione di Microbiologia, Università di Siena, Siena,² and Dipartimento Medico Wyeth-Lederle Italia S.p.A., Aprilia,³ Italy

Received 22 December 1999/Returned for modification 28 March 2000/Accepted 26 May 2000

	ABSTRACT

Top Abstract Text References

A new natural TEM-2 derivative, named TEM-72, was identified in a Proteus mirabilis strain and in a Morganella morganii strain isolated in Italy in 1999. Compared to TEM-1, TEM-72 contains the following amino acid substitutions: Q39K, M182T, G238S, and E240K. Kinetic analysis showed that TEM-72 exhibits an extended-spectrum activity, including activity against oxyimino-cephalosporins and aztreonam. Expression of bla_TEM-72 in Escherichia coli was capable of decreasing the host susceptibility to the above drugs.

	TEXT

Top Abstract Text References

Extended-spectrum -lactamases (ESBLs) are a group of enzymes that confer resistance to oxyimino cephalosporins and monobactams (7, 8, 11, 18). Most ESBLs found in clinical isolates of the Enterobacteriaceae are plasmid-borne variants of the original TEM-1 and SHV-1 enzymes in which one or more amino acid substitutions expand the substrate specificity (2-4, 21). Currently, almost 100 of these variants have been described (K. Bush and G. Jacoby, http://www.lahey.org/studies/webt.htm).

In this work we report on the characterization of a new natural TEM derivative with ESBL activity, named TEM-72, identified during a survey that was recently undertaken to evaluate the prevalence of ESBL-producing isolates of Enterobacteriaceae in Italian hospitals.

Proteus mirabilis (isolate FI-14) and Morganella morganii (isolate FI-13) were simultaneously isolated from a decubitus ulcer of an inpatient at the Careggi Hospital of Florence, Italy, in 1999. Escherichia coli DH5 (Life Technologies, Milan, Italy) was used as a recipient for the ESBL-carrying plasmids. Media were from Difco Laboratories (Detroit, Mich.). Piperacillin and tazobactam were from Wyeth-Lederle (Catania, Italy), aztreonam and cefepime were from Bristol-Myers Squibb (Wallingford, Conn.), cefotaxime and cefpirome were from Hoechst Marion Roussel (Romainville, France), ceftazidime was from Glaxo-Wellcome (Verona, Italy), nitrocefin was from Unipath (Milan, Italy), clavulanic acid was from SmithKline Beecham (Brentford, United Kingdom), and other antibiotics were from Sigma Chemical Co. (St. Louis, Mo.). MICs were determined by a broth macrodilution procedure as recommended by the National Committee for Clinical Laboratory Standards (13). Colony and Southern blot hybridizations were performed as described (16) using random-primed ³²P-labeled DNA probes comprised of PCR-generated amplicons containing the bla_TEM-1 (19) or the bla_SHV-1 (1) genes. Plasmids were purified by the alkaline lysis method (16). Electroporation was performed using a Gene Pulser apparatus (Bio-Rad Laboratories, Richmond, Calif.) according to the manufacturer's instructions. PCR amplification of bla_TEM alleles was carried out as described previously (15) using the AmpliTaq Gold DNA polymerase (Perkin-Elmer, Milan, Italy). Sequencing was performed on both strands using a dRhodamine Terminator Cycle Sequencing Ready reaction kit, an ABI PRISM 377 DNA Sequencer (Perkin-Elmer), and custom sequencing primers. Sequencing was performed in triplicate on PCR products derived from three independent reactions. TEM-72 was purified from E. coli DH5(pPM-14) grown overnight at 37°C, aerobically, in 6 liters of brain heart infusion broth containing 30 µg of ceftazidime per ml. Cells were harvested, and a sonic extract (sonicated five times for 30 s each time, at 60 W) was prepared in 80 ml of 50 mM Tris-HCl buffer (pH 8.0) (TB) and cleared by high-speed centrifugation (105,000 × g for 30 min at 4°C). The cleared extract was loaded onto a Q-Sepharose FF column (2 by 20 cm; Amersham Pharmacia Biotech, Milan, Italy) equilibrated with TB, and the -lactamase was eluted with a linear gradient of NaCl (0.2 to 0.8 M) in TB. The fractions containing cefotaxime-hydrolyzing activity were pooled, dialyzed against TB, and loaded onto a Superdex G75 FF column (1 by 60 cm; Amersham Pharmacia Biotech) equilibrated with TB. The active fractions were dialyzed against 25 mM bis(2-hydroxethyl)iminotris(hydroxymethyl)methane (Bis-Tris buffer (pH 7.1), and loaded onto a Mono P HR 5/20 column (Amersham Pharmacia Biotech) equilibrated with the same buffer. The proteins were eluted with 25 ml of 10-fold-diluted Polybuffer 74 in the pH range of 7.1 to 4. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed by the method of Laemmli (12). Analytical isoelectric focusing and zymogram detection of -lactamase bands using the chromogenic substrate nitrocefin were performed as described previously (14). Kinetic parameters were determined by monitoring the hydrolysis of each substrate at 30°C in 50 mM sodium phosphate buffer (pH 6.7) with a Lambda 2 spectrophotometer (Perkin-Elmer). The total reaction volume was 1 ml, and the enzyme concentration in the reaction was in the range 190 to 900 nM. Kinetic parameters were determined by analyzing either the complete hydrolysis time courses (5) or under initial-rate conditions (17). K_m values lower than 25 µM were calculated as K_i as described previously (5), using 80 µM nitrocefin as the reporter substrate. Inhibition by clavulanic acid and tazobactam was monitored using 80 µM cefazolin as the reporter substrate.

Identification of a new natural TEM-derived ESBL in M. morganii FI-13 and in P. mirabilis FI-14. M. morganii FI-13 and P. mirabilis FI-14 were resistant to amoxicillin, piperacillin, cefotaxime, ceftazidime, and aztreonam but susceptible to piperacillin-tazobactam and carbapenems. FI-14 was also susceptible to amoxicillin-clavulanate and cefoxitin, while FI-13 was resistant to these compounds (Table 1). In both isolates ESBL production was suspected on the basis of the susceptibility pattern and a positive double-disk synergy test (9) with clavulanate and ceftazidime (data not shown).

View this table: [in this window] [in a new window]   TABLE 1.   MICs of various -lactams for strains used in this study

A colony-blot hybridization revealed the presence of bla_TEM- but not of bla_SHV-related sequences in either strain (data not shown). A plasmid of approximately 40 kb was detected in either strain. These plasmids, named pMN-13 and pPM-14, respectively, exhibited apparently identical restriction profiles with HindIII, BglII, EcoRI, EcoRV, and PstI (Fig. 1 and data not shown). A Southern blot hybridization revealed that the bla_TEM-related sequences were plasmid borne. With both plasmids the probe hybridized to single restriction fragments after digestion with HindIII, BglII, EcoRI, and EcoRV and with two restriction fragments after digestion with PstI (Fig. 1 and data not shown).

View larger version (83K): [in this window] [in a new window]   FIG. 1.   (A) Agarose gel electrophoresis of the plasmid pPM14, purified from P. mirabilis FI-14. Lanes: U, uncut; H, B, R, V, P, after digestion with HindIII, BglII, EcoRI, EcoRV, and PstI, respectively. (B) Results of Southern blot analysis of the gel shown in panel A using the blaTEM probe. DNA size standards (in kilobase pairs) are shown on the left. Identical results were obtained with plasmid pMN-13 purified from M. morganii FI-13 and with plasmids purified from the respective E. coli transformants.

Ceftazidime resistance could be transferred to E. coli DH5 by electroporation with the plasmid preparations and selection on medium containing 50 µg of the antibiotic per ml. The E. coli transformants exhibited a positive double-disk synergy test with clavulanate and ceftazidime and showed a plasmid profile identical to that of FI-13 and FI-14. Analytical isoelectric focusing of the crude extracts of DH5(pMN-13) and of DH5(pPM-14) revealed, in either case, the presence of a single band of -lactamase activity of pI 5.9 (data not shown).

The sequences of the bla_TEM alleles carried by pMN-13 and pPM-14 were determined and turned out to be identical. Compared to TEM-1 (19), the encoded enzyme showed a unique array of amino acid changes (Q39K, M182T, G238S, and E240K). The enzyme was named TEM-72.

Purification and characterization of TEM-72. TEM-72 was purified from E. coli DH5(pPM-14) by three chromatographic steps (Table 2), yielding a preparation that was >95% pure as evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (data not shown). The isoelectric pH of the purified enzyme was 5.9 (data not shown).

View this table: [in this window] [in a new window]   TABLE 2.   Summary of the purification steps of TEM-72 -lactamase from E. coli DH5(pPM-14)

Measurement of the kinetic parameters revealed that, in addition to penicillins and older cephalosporins, TEM-72 also hydrolyzes oxyimino-cephalosporins and aztreonam, but not cefoxitin (Table 3). The highest catalytic efficiencies (k_cat/K_m, where k_cat is the catalytic rate constant) were observed with penicillins, narrow-spectrum cephalosporins, and cefotaxime. Lower values were observed with other oxyimino-cephalosporins. Aztreonam was slowly hydrolyzed, but the very high affinity of TEM-72 for this compound resulted in a k_cat/K_m ratio that was in the range of those observed with oxyimino-cephalosporins. Tazobactam behaved as a competitive inhibitor (K_i, 3.1 nM). With clavulanate a progressive inactivation was observed: at a molar ratio of 100:1 (clavulanate/enzyme) no reactivation of the enzyme was detected after prolonged (18-h) incubation.

View this table: [in this window] [in a new window]   TABLE 3.   Kinetic parameters determined with the TEM-72 -lactamase purified from E. coli DH5(pPM-14)

E. coli DH5(pMN-13) and E. coli DH5(pPM-14) showed comparable patterns of decreased susceptibility to penicillins, narrow-spectrum cephalosporins, oxyimino-cephalosporins and aztreonam. The MICs of cefotaxime and cefepime, although increased, remained below the breakpoint for resistance. In these cases, however, a resistant phenotype was observed using a larger bacterial inoculum (5 × 10⁷ CFU) (data not shown). Clavulanic acid and tazobactam were able to restore the susceptibility to amoxicillin and piperacillin, respectively (Table 1).

These results were overall consistent with kinetic data and indicate that a spread of TEM-72 could be very dangerous in the clinical setting.

Concluding remarks. TEM-72 is a new natural TEM-type ESBL apparently derived from TEM-2, on the basis of the presence of the Q39K mutation. Of the three additional mutations present in TEM-72, M182T is known to act as a global suppressor of missense mutations (6), while G238S and E240K are known to be involved in the extension of substrate specificity to oxyimino-cephalosporins and monobactams (10, 20). It should be noted, however, that G238S and E240K have rarely been found together in natural TEM variants and that, in those instances when they have been (TEM-42, TEM-47, TEM-48, and TEM-49), the two mutations were always associated with additional ones (http://www.lahey.org/studies/webt.htm) of uncertain significance (11). This suggests that the presence of additional mutations could be relevant for the stability and/or function of a mutant enzyme in which G238S and E240K are simultaneously present and that, in TEM-72, a similar role could be played by the M182T global suppressor. Interestingly, kinetic parameters of TEM-72 with cephaloridine, cefotaxime, and ceftazidime were apparently different (both K_m and k_cat values were lower) from those previously reported for a simple G238S-E240K mutant of TEM-1 (21), suggesting that in a similar background one or both of the additional mutations found in TEM-72 (Q39K and/or M182T) could be relevant to the conformation of the active site. It will be interesting to further investigate this point by comparative kinetic analysis of the appropriate TEM variants constructed by site-directed mutagenesis.

Nucleotide sequence accession numbers. (The nucleotide sequences reported in this paper have been submitted to the EMBL/GenBank database and assigned the accession numbers AF157413 and AF157553.)

	ACKNOWLEDGMENTS

We acknowledge Wyeth-Lederle Italia S.p.A. for a generous educational grant. Part of this work was also supported by grants from the Italian National Research Council (C.N.R.) and the Italian Ministry of Education (M.U.R.S.T.). We also acknowledge the contribution of the Italian ESBL Study Group: A. Toniolo and F. Luzzaro (Varese), P. Nicoletti (Florence), G. Gesu and R. Vaiani (Milan), G. Fortina (Novara), G. Nicoletti and G. Bonfiglio (Catania), G. Fadda and T. Spanu (Rome), G. Miragliotta (Bari), F. Menichetti (Pisa), and E. Magliano and G. Ortisi (Milan).

	FOOTNOTES

^* Corresponding author. Mailing address: Dipartimento di Scienze e Tecnologie Biomediche, Cattedra di Enzimologia, Università di L'Aquila, Località Coppito, Via Vetoio, 67100 L'Aquila, Italy. Phone: 39 0862 433455. Fax: 39 0862 433433. E-mail: amicosante{at}cc.univaq.it.

	REFERENCES

Top Abstract Text References

1.	Barthélémy, M., J. Peduzzi, and R. Labia. 1988. Complete amino acid sequence of p453-plasmid-mediated PIT-2 -lactamase (SHV-1). Biochem. J. 251:73-79[Medline].
2.	Bonnet, R., C. De Champs, D. Sirot, C. Chanal, R. Labia, and J. Sirot. 1999. Diversity of TEM mutants in Proteus mirabilis. Antimicrob. Agents Chemother. 43:2671-2677[Abstract/Free Full Text].
3.	Bradford, P. A., N. V. Jacobus, N. Bhachech, and K. Bush. 1996. TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum -lactamases. Antimicrob. Agents Chemother. 40:260-262[Abstract].
4.	Bradford, P. A., C. E. Cherubin, V. Idemyor, B. A. Rasmussen, and K. Bush. 1994. Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing -lactamases in a single isolate. Antimicrob. Agents Chemother. 38:761-766[Abstract/Free Full Text].
5.	De Meester, F., B. Joris, G. Reckinger, C. Bellefroid-Bourguignon, J. M. Frère, and S. G. Waley. 1987. Automated analysis of enzyme inactivation phenomena. Biochem. J. 36:2393-2403.
6.	Huang, W., and T. Palzkill. 1997. A natural polymorphism in -lactamase is a global suppressor. Proc. Natl. Acad. Sci. USA 94:8801-8806[Abstract/Free Full Text].
7.	Jacoby, G. A., and A. A. Medeiros. 1991. More extended-spectrum -lactamases. Antimicrob. Agents Chemother. 35:1697-1704[Free Full Text].
8.	Jacoby, G. A. 1997. Extended-spectrum -lactamases and other enzymes providing resistance to oxyimino--lactams. Infect. Dis. Clin. N. Am. 11:875-887[CrossRef][Medline].
9.	Jarlier, V., M. H. Nicholas, G. Fournier, and A. Philippon. 1988. Extended broad-spectrum -lactamases conferring transferable resistance to newer -lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10:867-878[Medline].
10.	Knox, J. R. 1995. Extended-spectrum and inhibitor-resistant TEM-type -lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39:2593-2601[Medline].
11.	Labia, R., A. Morand, A. Tiwari, D. Sirot, and A. Petit. 1988. Interactions of new plasmid-mediated -lactamases with third generation cephalosporins. Rev. Infect. Dis. 10:885-891[Medline].
12.	Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of bacteriophage T4. Nature (London) 227:680-685[CrossRef][Medline].
13.	National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14.	Oliva, B., M. C. Marinucci, G. Amicosante, A. Oratore, and P. M. Bennet. 1987. Citrobacter diversus ULA27 produces two forms of a chromosomal -lactamase. J. Antimicrob. Chemother. 20:23-35[Abstract/Free Full Text].
15.	Perilli, M., A. Felici, N. Franceschini, A. De Santis, L. Pagani, F. Luzzaro, A. Oratore, G. M. Rossolini, J. R. Knox, and G. Amicosante. 1997. Characterization of a new TEM-derived -lactamase produced in a Serratia marcescens strain. Antimicrob. Agents Chemother. 41:2374-2382[Abstract].
16.	Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
17.	Segel, I. H. 1976. Biochemical calculations, 2nd ed., p. 236-241. John Wiley & Sons, New York, N.Y.
18.	Sirot, J., C. Chanal, A. Petit, D. Sirot, R. Labia, and G. Gerbaud. 1988. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated -lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Rev. Infect. Dis. 10:850-859[Medline].
19.	Sutcliffe, J. G. 1978. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc. Natl. Acad. Sci. USA 75:3737-3741[Abstract/Free Full Text].
20.	Venkatachalam, K. V., W. Huang, M. La Rocco, and T. Palzkill. 1994. Characterization of TEM-1 -lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. J. Biol. Chem. 269:23444-23450[Abstract/Free Full Text].
21.	Yang, Y., N. Bhachech, P. A. Bradford, B. D. Jett, D. F. Sahm, and K. Bush. 1998. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli isolates producing TEM-10 and TEM-43 -lactamases from St. Louis, Missouri. Antimicrob. Agents Chemother. 42:1671-1676[Abstract/Free Full Text].

This article has been cited by other articles:

• Ho, P. L., Ho, A. Y. M., Chow, K. H., Wong, R. C. W., Duan, R. S., Ho, W. L., Mak, G. C., Tsang, K. W., Yam, W. C., Yuen, K. Y. (2005). Occurrence and molecular analysis of extended-spectrum {beta}-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002. J Antimicrob Chemother 55: 840-845 [Abstract] [Full Text]  
• Kurokawa, H., Shibata, N., Doi, Y., Shibayama, K., Kamachi, K., Yagi, T., Arakawa, Y. (2003). A New TEM-Derived Extended-Spectrum {beta}-Lactamase (TEM-91) with an R164C Substitution at the {Omega}-Loop Confers Ceftazidime Resistance. Antimicrob. Agents Chemother. 47: 2981-2983 [Abstract] [Full Text]  
• Barlow, M., Hall, B. G. (2003). Experimental Prediction of the Natural Evolution of Antibiotic Resistance. Genetics 163: 1237-1241 [Abstract] [Full Text]  
• Schroeder, W. A., Locke, T. R., Jensen, S. E. (2002). Resistance to {beta}-Lactamase Inhibitor Protein Does Not Parallel Resistance to Clavulanic Acid in TEM {beta}-Lactamase Mutants. Antimicrob. Agents Chemother. 46: 3568-3573 [Abstract] [Full Text]  
• Pagani, L., Migliavacca, R., Pallecchi, L., Matti, C., Giacobone, E., Amicosante, G., Romero, E., Rossolini, G. M. (2002). Emerging Extended-Spectrum {beta}-Lactamases in Proteus mirabilis. J. Clin. Microbiol. 40: 1549-1552 [Abstract] [Full Text]  
• Perilli, M., Segatore, B., Massis, M. R. D., Franceschini, N., Bianchi, C., Rossolini, G. M., Amicosante, G. (2002). Characterization of a New Extended-Spectrum {beta}-Lactamase (TEM-87) Isolated in Proteus mirabilis during an Italian Survey. Antimicrob. Agents Chemother. 46: 925-928 [Abstract] [Full Text]  
• Barlow, M., Hall, B. G. (2002). Predicting Evolutionary Potential: In Vitro Evolution Accurately Reproduces Natural Evolution of the TEM {beta}-Lactamase. Genetics 160: 823-832 [Abstract] [Full Text]  
• Perilli, M., Dell'Amico, E., Segatore, B., de Massis, M. R., Bianchi, C., Luzzaro, F., Rossolini, G. M., Toniolo, A., Nicoletti, G., Amicosante, G. (2002). Molecular Characterization of Extended-Spectrum {beta}-Lactamases Produced by Nosocomial Isolates of Enterobacteriaceae from an Italian Nationwide Survey. J. Clin. Microbiol. 40: 611-614 [Abstract] [Full Text]  
• Spanu, T., Luzzaro, F., Perilli, M., Amicosante, G., Toniolo, A., Fadda, G. (2002). Occurrence of Extended-Spectrum {beta}-Lactamases in Members of the Family Enterobacteriaceae in Italy: Implications for Resistance to {beta}-Lactams and Other Antimicrobial Drugs. Antimicrob. Agents Chemother. 46: 196-202 [Abstract] [Full Text]  
• Bradford, P. A. (2001). Extended-Spectrum {beta}-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin. Microbiol. Rev. 14: 933-951 [Abstract] [Full Text]  
• de Champs, C., Monne, C., Bonnet, R., Sougakoff, W., Sirot, D., Chanal, C., Sirot, J. (2001). New TEM Variant (TEM-92) Produced by Proteus mirabilis and Providencia stuartii Isolates. Antimicrob. Agents Chemother. 45: 1278-1280 [Abstract] [Full Text]  
• Sideraki, V., Huang, W., Palzkill, T., Gilbert, H. F. (2000). A secondary drug resistance mutation of TEM-1 beta -lactamase that suppresses misfolding and aggregation. Proc. Natl. Acad. Sci. USA 10.1073/pnas.011454198v1 [Abstract] [Full Text]  
• Sideraki, V., Huang, W., Palzkill, T., Gilbert, H. F. (2001). A secondary drug resistance mutation of TEM-1 beta -lactamase that suppresses misfolding and aggregation. Proc. Natl. Acad. Sci. USA 98: 283-288 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perilli, M. Articles by Amicosante, G. Search for Related Content PubMed PubMed Citation Articles by Perilli, M. Articles by Amicosante, G.